Previous Close | 0.5886 |
Open | 0.5900 |
Bid | 0.5800 x 1300 |
Ask | 0.6300 x 800 |
Day's Range | 0.5520 - 0.6119 |
52 Week Range | 0.4500 - 5.0800 |
Volume | |
Avg. Volume | 732,085 |
Market Cap | 15.082M |
Beta (5Y Monthly) | 0.40 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.8580 |
Earnings Date | May 16, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 8.67 |
Subscribe to Yahoo Finance Plus to view Fair Value for ADIL
AD04 achieved statistically significant mean reduction in heavy drinking days among pre-specified group of heavy drinkers, compared to placebo, with an approximately 79% reduction from baseline drinking AD04 demonstrated statistically significant difference in AUD severity, as compared to placebo, with an 84% decrease in the number of heavy drinking patients meeting the criteria for AUD diagnosis Company plans to submit ONWARD results to both European and U.S. regulatory agencies Conference call
Adial Pharmaceuticals Inc's (NASDAQ: ADIL) ONWARD Phase 3 study of AD04 for Alcohol Use Disorder (AUD) achieved a statistically significant mean reduction in heavy drinking days compared to placebo. Trial Results: AD04 achieved a statistically significant mean reduction compared to placebo from baseline at month six in heavy drinking days among "heavy drinkers" (average <10 drinks per drinking day), accounting for around two-thirds of the trial population. A similar trend was seen in the combine
Company to host conference call on Wednesday, July 20, 2022, at 1 PM ETCHARLOTTESVILLE, Va., July 18, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it plans to report topline results from the Company’s ONWARD™ Phase 3 clinical trial on Wednesday, July 20, 2022. The Company plan